Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25718953 | 1.00 | CYP4F2 (0.47) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL23884691 | 0.90 | MEN1 (0.39) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL23884841 | 0.85 | ALDH1A1 (0.37) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL23884840 | 0.85 | ALDH1A1 (0.37) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL30177234 | 0.83 | HCRTR2 (0.51) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL25718949 | 0.82 | CYP4F2 (0.47) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL30177177 | 0.82 | CYP4F2 (0.47) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL23884814 | 0.80 | MEN1 (0.35) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL30177225 | 0.80 | MEN1 (0.35) | CYP4F2CYP4A11MEN1KMT2APOLB | |
| SCHEMBL30177205 | 0.78 | MAPT (0.44) | MEN1KMT2APOLBALDH1A1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126832-B1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20230192611-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4126832-A1 | MODULATORS OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192611-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | CYP4F2 632/4885CYP4A11 970/4885MEN1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.